Since 1915, Danish pharmaceutical company Lundbeck has dedicated itself exclusively to one mission, improving lives affected by brain diseases.
Operating under the guiding principle “Progress in Mind,” Lundbeck develops and delivers treatments for depression, schizophrenia, migraine, and dementia-related conditions that millions of Ukrainians face daily.
Delta Medical will soon partner with Lundbeck to bring these specialized therapies to Ukrainian clinicians and patients, combining Lundbeck’s century of neuroscience expertise with Delta’s established infrastructure across Ukraine.
For most pharmaceutical companies, the brain represents one therapeutic area among many. For Lundbeck, it is everything.
Founded on August 14, 1915 in Copenhagen, the company has spent 110 years pursuing a single question: how do we help people whose lives are disrupted by conditions affecting mood, thinking, perception, and daily function?
This focus produces depth rather than breadth. Lundbeck’s research teams concentrate on understanding the neurobiology of depression, the circuit dysfunction underlying schizophrenia, the mechanisms driving migraine, and the behavioral symptoms that emerge as dementia progresses.
The result is a portfolio built not around market size but around unmet clinical need: therapies designed for the specific challenges psychiatrists and neurologists encounter when treating conditions where standard approaches fall short.
What Lundbeck Brings to Ukrainian Clinicians
Ukrainian psychiatrists manage substantial mental health burdens, with depression and anxiety disorders affecting significant portions of the population and schizophrenia requiring long-term, coordinated care. Lundbeck’s portfolio addresses these realities with mechanistic variety and formulation innovation.
For major depressive disorder, Lundbeck offers Brintellix (vortioxetine), a multimodal antidepressant that modulates serotonin activity across multiple receptor subtypes. While traditional SSRIs focus primarily on serotonin reuptake, vortioxetine’s broader receptor profile targets both mood and cognitive symptoms; the concentration difficulties, memory problems, and mental fog that patients describe as being “unable to think clearly” even when sadness lifts.
This matters in Ukraine’s demanding work and wartime environments where functional recovery means more than feeling better; it can include improved ability to work, maintain relationships and manage daily activities.
In schizophrenia, Lundbeck has developed expertise in both acute and maintenance treatment approaches, with particular focus on long-acting injectable formulations that address one of psychiatry’s most persistent challenges: adherence. When patients stop taking daily oral medication whether due to stigma, forgetfulness, lack of insight, or simply decision fatigue then relapse follows quickly.
Long-acting formulations ensure consistent plasma levels, reduce the burden of daily pill-taking, and give clinicians early visibility when a patient misses a scheduled injection. For Ukrainian patients experiencing complex social and economic pressures, innovations in extended-release delivery may help support sustained stability and reduce relapse risk for some patients.
Migraine affects roughly 15% of adults worldwide, with women experiencing three times the burden of men. Lundbeck’s Vyepti (eptinezumab) represents a fundamentally different approach to prevention. As a monoclonal antibody targeting calcitonin gene-related peptide (CGRP), Vyepti blocks the molecular pathway that triggers migraine attacks rather than broadly dampening nervous system activity the way traditional preventives do. Administered quarterly by intravenous infusion, it reduces monthly migraine days for patients whose quality of life has been eroded by unpredictable, disabling headaches that derail work, family life, and social engagement.
Vyepti (eptinezumab) was registered in the European Union in 2022. Vyepti is not yet registered in Ukraine.
Perhaps most striking is Lundbeck’s work in Alzheimer’s-related agitation. Rexulti (brexpiprazole) became the first medication approved by the US FDA specifically for agitation in dementia due to Alzheimer’s disease in May 2023. Families caring for loved ones with dementia know the exhaustion and heartbreak of managing restlessness, verbal outbursts, physical aggression, and pacing that can emerge as the disease progresses.
Non-pharmacological approaches remain first-line, but when behavioral interventions prove insufficient, Rexulti offers a targeted option that addresses agitation without the heavy sedation or increased fall risk associated with certain other approaches.
What This Means for Patients
Brain diseases share a common feature: they steal the person you were. Depression removes motivation, joy, and the ability to imagine a future. Schizophrenia fractures perception and thinking, making it difficult to distinguish internal experiences from external reality. Migraine transforms ordinary light and sound into triggers for hours of incapacitating pain. Dementia erases memory, personality, and eventually the capacity for self-care.
Lundbeck’s therapies aim to give people back pieces of themselves. Antidepressants restore energy and interest in activities that once brought pleasure. Antipsychotics quiet intrusive voices and organize chaotic thoughts. Migraine preventives reduce the number of days each month lost to headache. Medications for agitation help people with dementia remain calmer and more comfortable while reducing caregiver burden.
These are not cures.
They are tools for managing chronic conditions. Much like insulin for diabetes or antihypertensives for cardiovascular disease. Success means symptom reduction, functional improvement, and better quality of life over months and years.
Prescribing decisions depend on individual medical history, previous treatment responses, potential side effects, and patient preferences regarding daily pills versus periodic injections.
Lundbeck’s Commitment to Ukraine
Lundbeck has been a long-term partner to Ukrainian physicians, psychiatrists, and neurologists. Sharing emerging evidence on treatment regimens at medical congresses, symposia, and regional educational events, and supporting clinical decision-making through ongoing dialogue with key opinion leaders and medical affairs professionals across the country.
This commitment to advancing brain health care in Ukraine continues as Lundbeck expands access to new therapies, maintains robust pharmacovigilance systems that meet both Ukrainian and global safety reporting standards, and strengthens collaboration with local healthcare institutions.
Starting soon, Delta Medical will assist in the marketing, sales, and distribution of Lundbeck products across Ukraine. This partnership leverages Delta’s deep experience in regulatory affairs, market access, and medical education within Ukrainian healthcare systems.
For clinicians, it means reliable supply, responsive medical information services, and educational programs tailored to Ukrainian clinical practice patterns. For patients, it means consistent access to therapies that have improved outcomes in Western European and North American populations.
Why Focus Matters
Pharmaceutical companies that divide attention across oncology, immunology, cardiovascular disease, and infectious disease must balance competing priorities and resource allocation. Lundbeck’s exclusive focus on the brain means every research program, every clinical trial, every medical education initiative serves one goal: better outcomes for people with neurological and psychiatric conditions.
For Ukrainian patients and clinicians, this translates to working with partners who understand that brain diseases require long-term management, that adherence challenges are not moral failures but predictable obstacles, and that functional recovery means returning to work, maintaining relationships, and participating in family life.
Delta Medical is proud to assist Lundbeck in bringing this philosophy to Ukraine.
About Delta Medical
Delta Medical is a Swiss pharmaceutical company specializing in the marketing and distribution of pharmaceuticals, medical devices, and clinical nutrition across Ukraine, CIS, and EAEU territories. We combine regulatory affairs and market access capabilities with deep therapeutic expertise in oncology and specialty care. Our teams deliver end-to-end commercialization, medical engagement, and real-world implementation. Explore partnership opportunities at www.deltaswiss.eu.
